Market Failure? kENUP and YUVEDO High-Level Online Event Kick-starts Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases.
21.9.2020 11:14:00 EEST | Business Wire | Press release
On Friday, 18 September 2020, YUVEDO Foundation and kENUP Foundation held a high-level online conference to kick-start an open public call for projects tackling the growing threat of Parkinson’s (PD) and other neurodegenerative diseases (NDD). Despite the predictable medical, social and economic challenges of NDDs, too little has happened in recent years to address the underlying causes of NDDs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005283/en/
Market and Regulatory Failure? High-Level Online Conference Kick-starts Open Public Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases (Photo: Business Wire)
An expert report by Professor Maier-Rigaud of NERA Economic Consulting presented at the conference, showed that there are indications for market and regulatory failure around the development of interventions against PD and other NDDs: High risk in product development is associated with massive cost but little potential profit. This has meant that many pharmaceutical companies have stopped their R&D investment in drugs or biologicals for the prevention and treatment of NDDs.
‘Project Brainstorm aims at developing a financing mechanism setting the right incentives to eliminate underlying market failures’ says Jörg Karenfort, Co-Founder of YUVEDO Foundation and partner at DENTONS.
‘Project Brainstorm developed by patients with broad support from leading researchers constitutes a timely response to the potential market failures underlying the development of interventions against neurodegenerative diseases. I support the need for further empirical research into these issues, ideally combined with a blueprint project such as the innovative Brainstorm Fund project’ said Katarina Barley, Vice-President of the European Parliament.
Holm Keller, Executive Chairman of kENUP Foundation said: ‘Brainstorm aims at reviving the fight against NDDs by initiating a new innovative financing mechanism providing venture loans at preferential terms to incorporated, scientifically promising projects not yet pursued by the pharmaceutical industry. This will help extend the deal-flow in the domain of NDDs.’
‘In order to jumpstart and accelerate the fight against diseases like Parkinson’s and Alzheimer’s I call on everyone to contribute to Project Brainstorm. YUVEDO Foundation is addressing an important public health issue that needs to be solved sooner than later’, added Elmar Brok, former Member and Committee Chair of the European Parliament.
Brainstorm is currently scouting relevant scientific and commercial communities for projects that develop interventions against neurodegenerative diseases and could contribute to the success of the portfolio. Companies interested in working with Brainstorm should contact Brainstorm at www.brainstormfund.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200921005283/en/
Contact information
Tobias Mac-Lean
maclean@kenup.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 22:30:00 EET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 22:15:00 EET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 20:06:00 EET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
InterSystems nimittänyt terveydenhuoltotoiminnan johtajaksi tohtori Tim Ferrisin, entisen NHS- ja Mass General ‑johtajan26.3.2026 20:00:00 EET | Tiedote
InterSystems on luovien datateknologiaratkaisujen tarjoaja, jonka ratkaisuihin on tallennettu yli miljardi terveystietotietuetta maailmanlaajuisesti. Yritys ilmoitti tänään nimittäneensä terveydenhuoltotoiminnan johtajaksi lääketieteen tohtori Tim Ferrisin. Nimityksestä ilmoitettiin samaan aikaan, kun terveydenhuoltoalan johtajat kokoontuvat vuoden 2026 HIMSS Global Health Conference & Exhibition ‑tapahtumaan. Roolissaan Ferris pääsee soveltamaan kattavaa toimialakokemustaan, kun hän ohjaa yrityksen terveydenhuoltoratkaisujen kliinistä ja strategista suuntaa maailmanlaajuisesti. Laajan kokemuksensa turvin hän toimii maailmanlaajuisten terveydenhuoltojärjestelmien ja hallitusten strategisena neuvonantajana ja suunnittelee räätälöityjä teknologiaratkaisuja, jotka perustuvat todellisiin johtotason tarpeisiin. Samalla hän edistää akateemista tutkimustaan terveysdata-arkkitehtuurista sekä johtaa julkista keskustelua tekoälyn ja hoidon tarjoamisen yhdistämisestä. Ferris tuo InterSystemsiin a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom